Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia

NCT01441882 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Refractory Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia
Stage II Chronic Lymphocytic Leukemia
Stage III Chronic Lymphocytic Leukemia
Stage IV Chronic Lymphocytic Leukemia

Interventions

DRUG: Dasatinib
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

OHSU Knight Cancer Institute

Collaborators

[object Object]